HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors
Lei Guan,Bin Wu,Ting Li,Lynn A. Beer,Gaurav Sharma,Mingyue Li,Chin Nien Lee,Shujing Liu,Changsong Yang,Lili Huang,Dennie T. Frederick,Genevieve M. Boland,Guangcan Shao,Tatyana M. Svitkina,Kathy Q. Cai,Fangping Chen,Meng-Qiu Dong,Gordon B. Mills,Lynn M. Schuchter,Giorgos C. Karakousis,Tara C. Mitchell,Keith T. Flaherty,David W. Speicher,Youhai H. Chen,Meenhard Herlyn,Ravi K. Amaravadi,Xiaowei Xu,Wei Guo
DOI: https://doi.org/10.1038/s41467-022-31713-6
IF: 16.6
2022-07-14
Nature Communications
Abstract:Abstract The lack of tumor infiltration by CD8 + T cells is associated with poor patient response to anti-PD-1 therapy. Understanding how tumor infiltration is regulated is key to improving treatment efficacy. Here, we report that phosphorylation of HRS, a pivotal component of the ESCRT complex involved in exosome biogenesis, restricts tumor infiltration of cytolytic CD8 + T cells. Following ERK-mediated phosphorylation, HRS interacts with and mediates the selective loading of PD-L1 to exosomes, which inhibits the migration of CD8 + T cells into tumors. In tissue samples from patients with melanoma, CD8 + T cells are excluded from the regions where tumor cells contain high levels of phosphorylated HRS. In murine tumor models, overexpression of phosphorylated HRS increases resistance to anti-PD-1 treatment, whereas inhibition of HRS phosphorylation enhances treatment efficacy. Our study reveals a mechanism by which phosphorylation of HRS in tumor cells regulates anti-tumor immunity by inducing PD-L1 + immunosuppressive exosomes, and suggests HRS phosphorylation blockade as a potential strategy to improve the efficacy of cancer immunotherapy.
multidisciplinary sciences